Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Connecticut: - Smilow Cancer Hospital Care Center at Saint Francis — Hartford, Connecticut
- Smilow Cancer Center/Yale-New Haven Hospital — New Haven, Connecticut
- Yale University — New Haven, Connecticut
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Connecticut: - Smilow Cancer Hospital-Derby Care Center — Derby, Connecticut
- Smilow Cancer Hospital Care Center-Fairfield — Fairfield, Connecticut
- Smilow Cancer Hospital Care Center at Glastonbury — Glastonbury, Connecticut
- Smilow Cancer Hospital Care Center at Greenwich — Greenwich, Connecticut
- Smilow Cancer Hospital Care Center - Guilford — Guilford, Connecticut
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…
Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in Connecticut: - Yale University Yale Cancer Center — New Haven, Connecticut
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …
Sponsor: BeOne Medicines
NCT ID: NCT06943872
Sites in Connecticut: - Yale University Yale Cancer Center — New Haven, Connecticut
- Eastern Connecticut Hematology and Oncology — Norwich, Connecticut
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 3 Recruiting Industry
The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lympho…
Sponsor: Ono Pharmaceutical Co., Ltd.
NCT ID: NCT07104032
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 3 Recruiting Industry
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+),…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06784752
Sites in Connecticut: - Hartford Hospital — Hartford, Connecticut
- Yale New Haven Hospital — New Haven, Connecticut
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in Connecticut: - Saint Vincent's Medical Center (SVMC) — Bridgeport, Connecticut
- Hartford Hospital — Hartford, Connecticut
- Midstate Medical Center (MSMC) — Meriden, Connecticut
- The Hospital of Central Connecticut (HOCC) Cancer Center — New Britain, Connecticut
- William W. Backus Hospital — Norwich, Connecticut
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Connecticut: - Connecticut Children's Medical Center — Hartford, Connecticut
- Yale University — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory…
Sponsor: Curis, Inc.
NCT ID: NCT03328078
Sites in Connecticut: - Smilow Cancer Hospital at Yale-New Haven — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymph…
Sponsor: Dren Bio
NCT ID: NCT05475925
Sites in Connecticut: - Dren Investigational Site — New Haven, Connecticut
Phase 2 Recruiting Industry
The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for st…
Sponsor: AstraZeneca
NCT ID: NCT05952024
Sites in Connecticut: - Research Site — Stamford, Connecticut
Phase 2 Recruiting Academic/Other
BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA)…
Sponsor: Brown University
NCT ID: NCT04792502
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 2 Recruiting Academic/Other
Single-arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) or CHOEP in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T-cell…
Sponsor: Yale University
NCT ID: NCT05996185
Sites in Connecticut: - Yale Cancer Center, Clinical Trials Office — New Haven, Connecticut
Phase 2 Recruiting Academic/Other
This is a single arm, open label, multicenter study phase 2 study of pembrolizumab and brentuximab in subjects with relapsed/refractory CD30 positive T-cell lymphoma (including peripheral T-cell lymphoma and cutaneous T-cell lymphoma) who …
Sponsor: Yale University
NCT ID: NCT05313243
Sites in Connecticut: - Yale Smilow Cancer Hospital — New Haven, Connecticut
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Connecticut: - Yale University — New Haven, Connecticut
- Smilow Cancer Hospital Care Center-Trumbull — Trumbull, Connecticut
Phase 1 Recruiting Industry
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT05131022
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclona…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05272384
Sites in Connecticut: - Yale University — New Haven, Connecticut
Phase 1 Recruiting Industry
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be …
Sponsor: Arvinas Inc.
NCT ID: NCT06393738
Sites in Connecticut: - Clinical Trial Site — New Haven, Connecticut
Recruiting Network
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hyd…
Sponsor: Children's Oncology Group
NCT ID: NCT01790152
Sites in Connecticut: - Yale University — New Haven, Connecticut
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Connecticut: - Massive Bio SYNERGY-AI site — Hartford, Connecticut
- Massive Bio SYNERGY-AI site — Norwalk, Connecticut
Recruiting Network
This study assesses how blood cell growth patterns (clonal hematopoiesis) relate to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead …
Sponsor: Children's Oncology Group
NCT ID: NCT05705531
Sites in Connecticut: - Connecticut Children's Medical Center — Hartford, Connecticut
- Yale University — New Haven, Connecticut
Recruiting Academic/Other
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05978141
Sites in Connecticut: - Yale University (Data Collection Only) — New Haven, Connecticut
NA Recruiting Academic/Other
This study evaluates the feasibility and safety of bridging radiation therapy, including a novel method for comparing the effectiveness of hypofractionated versus hyperfractionated radiation therapy in participants with relapsed/refractory…
Sponsor: Yale University
NCT ID: NCT06898905
Sites in Connecticut: - Yale University — New Haven, Connecticut